1 TNF Blocker Safety: Lymphoma and Liver Failure Tim Coté MD MPH, Chief, Therapeutics & Blood Safety Branch, DE/OBE/CBER/FDA March 4, 2003.

Slides:

Advertisements

Similar presentations

The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.

Advertisements

Julianne Gee, MPH Immunization Safety Office

1 Proposed Pharmacovigilance Plan for H5N1 Influenza Virus Vaccine Patrick Caubel, MD, PhD Head of Pharmacovigilance North America February 27, 2007.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,

Anti-TNF-  Strategies in CHF: Data from Randomized, Controlled Clinical Trials Arthritis Advisory Committee March 4, 2003 Ellis F. Unger, M.D. Office.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.

Adverse Event Reports on Automatic External Defibrillators from Oscar H Tovar MD and Beverly Gallauresi RN, MPH Food and Drug Administration.

1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.

Arthritis Advisory Committee March 4, 2003 Presented at the Arthritis Advisory Committee meeting on March 4, 2003 by Jeffrey N. Siegel, M.D.

Single-Agent Lenalidomide in Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Bortezomib: Efficacy, Safety and Pharmacokinetics from the.

Safety & Efficacy Update on Approved TNF-Blocking Agents Jeffrey N. Siegel, M.D. OTRR, CBER / FDA Arthritis Advisory Committee March 4, 2003 Jeffrey N.

Epidemiology: Non-Hodgkin’s Lymphoma.

Safety data collected during clinical trials is incorporated into the product’s approved label. Regulatory reviewers monitor products’ safety profiles.

Accutane FDA (Section Name - Saver’s Initials) 3/9/00 12:50 PM 1 Introduction Russell Ellison, MD Chief Medical Officer Vice President, Medical Affairs.

Multiple Choice Questions for discussion

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.

ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,

Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.

Examples of ADE Surveillance Systems MedDRA ® Processing of Adverse Event Reports in ADE Surveillance Systems Amarilys Vega, M.D, M.P.H., Sonja Brajovic,

Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.

1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

1 Establishing a MedDRA Safety Surveillance Unit Thanh Van T. Doan, RPh PSI International Inc. Working With MedDRA The New Connaught Rooms London, UK 17.

From the Lab to Market Unit 3.04 Understanding Biotechnology research & Development.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

Concept Paper #3: Risk Assessment of Observational Data Session 1: Good Pharmacovigilance Practices Linda S. Hostelley on behalf of PhRMA.

1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.

DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.

Study Designs for Clinical and Epidemiological Research Carla J. Alvarado, MS, CIC University of Wisconsin-Madison (608)

Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.

1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.

Arthritis Advisory Committee March 4, 2003 Update on the Safety of TNF Blockers Li-ching Liang, M.D. FDA / CBER/ OTRR Arthritis Advisory Committee March.

FDA Risk Management Workshop – Day #3 April 11, 2003 Robert C. Nelson, Ph.D. RCN Associates, Inc Annapolis, MD, USA.

1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.

Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) combination therapy in front-line low-grade non-Hodgkin lymphoma (LG-NHL) is active.

A Claims Database Approach to Evaluating Cardiovascular Safety of ADHD Medications A. J. Allen, M.D., Ph.D. Child Psychiatrist, Pharmacologist Global Medical.

Good Pharmacovigilance Practices

FDA Office of Orphan Products Development

Teriparatide or LY Eli Lilly & Company NDA Metabolic-Endocrine Drugs Metabolic-Endocrine Drugs Advisory Committee Advisory Committee Bethesda,

FDA1 Overview of Postmarketing Safety Surveillance in FDA (For Drugs and Biologics) Min Chen, M.S., R.Ph. Min Chen, M.S., R.Ph. Associate Director Division.

Signal identification and development I.Ralph Edwards.

Descriptive study design

Minimum requirements for Pharmacovigilance in countries.

CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.

Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.

Initiatives Drive Pediatric Drug Development January 30, 2002.

Types of Studies. Aim of epidemiological studies To determine distribution of disease To examine determinants of a disease To judge whether a given exposure.

Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.

European Patients’ Academy on Therapeutic Innovation Special Populations.

Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.

Comments on FDA Concept Paper Sidney N. Kahn, MD, PhD President Pharmacovigilance & Risk Management, Inc. Risk Assessment of Observational.

1 BETTER APPROACHES TO MONITORING MEDICAL PRODUCT SAFETY ARE NEEDED.

Copyright restrictions may apply JAMA Pediatrics Journal Club Slides: Flaxseed in Pediatric Hyperlipidemia Wong H, Chahal N, Manlhiot C, Niedra E, McCrindle.

Research Activities at The Boston Collaborative Drug Surveillance Program; Boston University School of Public Health Susan Jick Professor of Epidemiology.

Detection & monitoring of ADR

Patient Focused Drug Development An FDA Perspective

Clinical Trials — A Closer Look

FDA Guidance for Industry and FDA Staff Summary of Public Notification of Emerging Postmarket Medical Device Signals (“Emerging Signals”) Effective: December.

Mortality and Antithrombotics: Focus on FAERS Repository

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events

Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,

Application of Biosimilars in RA IN Clinical Practice: Key Issues and Challenges

Patient Involvement in the Development and Safe Use of

Presentation transcript:

1 TNF Blocker Safety: Lymphoma and Liver Failure Tim Coté MD MPH, Chief, Therapeutics & Blood Safety Branch, DE/OBE/CBER/FDA March 4, 2003

2 Postmarketing Surveillance Clinicians and others can report adverse events associated with drugs Passive surveillance Greatest strength is as a means of signal generation

3 Characteristics of Postmarketing Reports: Voluntary for clinicians but mandatory for companies Often incomplete -Unreported cases and -Sketchy narratives Coded into MedDRA terminology with high sensitivity Causality assessments are tenuous by design Cannot generate incidence rates

4 Lymphomas with TNF Blockers Rich body of medical literature associating immunodisregulation and lymphoma; biologically plausible that TNF blockers might cause lymphoma Hundreds of thousands of patients on these drugs, increasing the public health importance of this Committee’s consideration. We have published a series of 26 lymphomas arising among people on TNF Blockers, but causality unclear.

5 Lymphomas and TNF Blockers: Current Understanding RA and NHL are associated; this complicates the problem. Placebo-controlled studies have been small. Manufacturer’s pre- and postmarketing cohort studies have short follow-up times relative to carcinogenesis.

6 Update: Lymphomas Reported to FDA following TNF blockers, 1/99-12/02

7 Reports of 158 Lymphomas Reported Among Persons Taking TNF Blockers, 1/99-12/02 Source: Reports to FDA MedWatch program

8 Patient Characteristics: Lymphoma among patients treated with TNF blockers InfliximabEtanerceptBoth Age: Median Range % Female55%63%59% Indication RA Crohn’s Other 73% 21% 6% 86% 0% 14% 79% 12% 11%

9 Histology of 158 Lymphomas among Patients with TNF Blockers, Reported to FDA 1/99-12/02 78 (49%) Lymphoma NOS 26 (16%) non-Hodgkin’s Lymphoma, NOS 23 (15%) B-cell lymphoma, NOS 20 (13%) Hodgkin’s Disease 6 (4%) T-cell Lymphoma 3 (2%) Mantle cell lymphoma 1 (1%) Plasmacytoma 1 (1%) Burkitt’s Lymphoma

10 Conclusions: Lymphoma among TNF blocker recipients They are poorly characterized. It has not been established if they are the same grade as the general population. Histologically, they may be consistent with lymphoma secondary to immunodeficiency. Clinical trials found increased NHL risk, but based on few observations. Assessment is complicated by RA-confounded increases. The number of cases of lymphoma among persons taking TNF Blockers is growing. FDA needs input from the AAC to assess causality and/or propose means to better evaluate causality.

11 Liver Failure Signal for Leflunomide, thus of interest for TNF Blockers In clinical trials, some patients on Infliximab showed elevated increased liver enzymes.

12 Infliximab-mediated ALT Increases PlaceboInfliximab RA Patients on MTX 25/85 (29%) 127/342 (37%) CD Patients w/o MTX 68/187 (36%) 160/385 (42%) -Increased ALT was predominately <2x ULN --No clinical sequelae

13 Analysis of Liver Failure Reports to FDA

14 Extraneous causes of hepatic impairment among 43 pts on TNF Blockers.

15 Conclusion: Liver Failure with TNF blockers Liver Failure with TNF Blockers appears to be a rare event While there are a large number of people on TNF blockers, chance occurrence is unlikely (1/10 6 in general pop); causality cannot be ruled out. Some concern remains warranted Further clinical data on remaining cases are pending.